| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3281 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3048 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2126 | 2017 |
| Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for … DT Cheng, TN Mitchell, A Zehir, RH Shah, R Benayed, A Syed, ... The Journal of molecular diagnostics 17 (3), 251-264, 2015 | 1832 | 2015 |
| Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... New England Journal of Medicine 375 (5), 443-453, 2016 | 1646 | 2016 |
| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1355 | 2017 |
| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633-641, 2018 | 1270 | 2018 |
| Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587, 2018 | 1036 | 2018 |
| Variant review with the integrative genomics viewer JT Robinson, H Thorvaldsdóttir, AM Wenger, A Zehir, JP Mesirov Cancer research 77 (21), e31-e34, 2017 | 951 | 2017 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 838 | 2018 |
| Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 720 | 2018 |
| Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ... Cell stem cell 21 (3), 374-382. e4, 2017 | 714 | 2017 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 598 | 2017 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 587 | 2019 |
| Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ... JCO precision oncology 1, 1-16, 2017 | 540 | 2017 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 538 | 2019 |
| Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 536 | 2018 |
| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 480 | 2020 |
| NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ... Modern Pathology 33 (1), 38-46, 2020 | 478 | 2020 |
| Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ... Science 364 (6439), 485-491, 2019 | 477 | 2019 |
